Altimmune, Inc. (ALT) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Altimmune, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.454 and in the ongoing regulatory conversation. 00:00:04.776 -- 00:00:09.802 The statistical significance achieved across a panel of NITs 00:00:09.802 -- 00:00:15.588 we are assessing in the IMPACT trial provides strong support for pemvidutite 00:00:15.588 -- 00:00:20.774 antifibrotic effects, which we will look to continue to assess in the upcoming 00:00:20.774 -- 00:00:23.795 48-week readout. 00:00:23.918 -- 00:00:29.443 Speaking of the 48-week readout, We look forward to assessing the data 00:00:29.443 -- 00:00:34.228 and the potential of a longer treatment duration on NEAT measurements, 00:00:34.228 -- 00:00:37.051 as well as further weight loss. 00:00:37.051 -- 00:00:42.336 Recall, we had early and significant MASH resolution in our 24-week 00:00:42.336 -- 00:00:47.621 biopsy data and strong evidence of antifibrotic activity supported 00:00:47.621 -- 00:00:54.326 by the NEAT analysis, along with the continuing weight loss and excellent tolerability. 00:00:55.448 -- 00:01:00.536 The emerging recognition that improvements in certain NITs are likely to translate to 00:01:00.536 -- 00:01:05.723 clinical improvement has led regulatory agencies to consider allowing 00:01:05.723 -- 00:01:10.751 the use of NIT data as a measure of efficacy in MASH clinical 00:01:10.751 -- 00:01:12.393 trial. 00:01:12.393 -- 00:01:17.681 In clinical practice, MASH patients are often diagnosed and courses 00:01:17.681 -- 00:01:22.769 of treatment determined based on these non-invasive tests, and the possibility of 00:01:22.769 -- 00:01:28.529 the regulatory agencies more closely aligning with clinical practice, 00:01:28.529 -- 00:01:35.114 bodes particularly well for pembidutite given the strength of our neat data. 00:01:35.756 -- 00:01:41.222 Dr. Mazen Nou...